Iovance Biotherapeutics (IOVA) – Analysts’ Weekly Ratings Changes

Iovance Biotherapeutics (NASDAQ: IOVA) has recently received a number of price target changes and ratings updates:

• 11/6/2026 – Iovance Biotherapeutics had its price target raised by Barclays from $18.00 to $19.00. They now have an “overweight” rating on the stock.
• 11/6/2026 – Iovance Biotherapeutics had its price target raised by Citizens Jmp from $8.00 to $12.00. They now have a “market outperform” rating on the stock.
• 11/3/2026 – Iovance Biotherapeutics had its price target raised by UBS Group from $7.00 to $8.00. They now have a “neutral” rating on the stock.
• 10/26/2026 – Iovance Biotherapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/13/2026 – Iovance Biotherapeutics had its price target raised by Barclays from $15.00 to $18.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Iovance Biotherapeutics had its price target raised by Robert W. Baird from $6.00 to $11.00. They now have a “neutral” rating on the stock.
• 9/30/2026 – Iovance Biotherapeutics had its price target raised by Wells Fargo & Company from $14.00 to $18.00. They now have an “overweight” rating on the stock.
• 9/29/2026 – Iovance Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/29/2026 – Iovance Biotherapeutics had its price target raised by HC Wainwright from $9.00 to $20.00. They now have a “buy” rating on the stock.
• 9/24/2026 – Iovance Biotherapeutics is now covered by The Goldman Sachs Group. They set a “buy” rating and a $15.00 price target on the stock.
• 9/24/2026 – Iovance Biotherapeutics is now covered by The Goldman Sachs Group. They set a “buy” rating and a $15.00 price target on the stock.
• 9/17/2026 – Iovance Biotherapeutics had its price target raised by Barclays from $13.00 to $15.00. They now have an “overweight” rating on the stock.

Iovance Biotherapeutics Trading Up 1.6%

IOVA stock traded up $0.13 during trading on Monday, reaching $8.17. The stock had a trading volume of 13,679,846 shares, compared to its average volume of 15,225,139. Iovance Biotherapeutics, Inc. has a 52 week low of $2.08 and a 52 week high of $15.37. The stock’s 50 day moving average is $11.38 and its two-hundred day moving average is $6.00. The firm has a market cap of $3.70 billion, a PE ratio of -15.42 and a beta of 0.88.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04. The business had revenue of $121.47 million during the quarter, compared to analyst estimates of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The company’s quarterly revenue was up 64.8% compared to the same quarter last year. On average, research analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.43 EPS for the current year.

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient.

The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.